Skandinaviska Enskilda Banken AB publ Sells 213,400 Shares of Eli Lilly And Co (LLY)

Skandinaviska Enskilda Banken AB publ decreased its stake in Eli Lilly And Co (NYSE:LLY) by 26.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 595,918 shares of the company’s stock after selling 213,400 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.06% of Eli Lilly And Co worth $63,948,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. Essex Financial Services Inc. increased its position in shares of Eli Lilly And Co by 1.8% during the 3rd quarter. Essex Financial Services Inc. now owns 37,472 shares of the company’s stock valued at $4,021,000 after purchasing an additional 676 shares during the period. Regal Investment Advisors LLC acquired a new position in shares of Eli Lilly And Co during the 3rd quarter valued at $331,000. Paragon Capital Management Ltd acquired a new position in shares of Eli Lilly And Co during the 3rd quarter valued at $203,000. Penserra Capital Management LLC increased its position in shares of Eli Lilly And Co by 372.7% during the 3rd quarter. Penserra Capital Management LLC now owns 18,673 shares of the company’s stock valued at $2,003,000 after purchasing an additional 14,723 shares during the period. Finally, Chicago Partners Investment Group LLC increased its position in shares of Eli Lilly And Co by 13.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 4,902 shares of the company’s stock valued at $527,000 after purchasing an additional 591 shares during the period. 76.17% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on the company. TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b+” rating in a research report on Tuesday. Societe Generale set a $106.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research report on Wednesday. ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday. Credit Suisse Group upgraded Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research report on Wednesday, October 31st. Finally, Wolfe Research assumed coverage on Eli Lilly And Co in a research report on Tuesday, October 23rd. They set a “market perform” rating and a $119.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Eli Lilly And Co presently has a consensus rating of “Buy” and a consensus target price of $111.19.

LLY opened at $112.21 on Friday. The firm has a market cap of $116.23 billion, a PE ratio of 26.22, a P/E/G ratio of 1.75 and a beta of 0.29. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.09. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $116.61.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.04. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The company’s revenue was up 7.1% compared to the same quarter last year. During the same period last year, the company posted $1.05 EPS. Equities research analysts forecast that Eli Lilly And Co will post 5.57 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.01%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is presently 52.57%.

In other news, major shareholder Eli & Co Lilly sold 700,000 shares of the firm’s stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the sale, the insider now owns 3,148,647 shares of the company’s stock, valued at $44,081,058. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $105.57, for a total value of $63,342.00. Following the completion of the sale, the insider now directly owns 3,530 shares of the company’s stock, valued at approximately $372,662.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,881,684 shares of company stock valued at $133,274,076. Corporate insiders own 0.11% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Skandinaviska Enskilda Banken AB publ Sells 213,400 Shares of Eli Lilly And Co (LLY)” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/11/10/skandinaviska-enskilda-banken-ab-publ-sells-213400-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: How are the companies in the S&P 500 selected?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply